Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia

Br J Clin Pharmacol. 1992 Nov;34(5):427-30.

Abstract

The effect of lovastatin on erythrocyte membrane composition and fluidity was investigated in eight patients with severe hypercholesterolaemia (mean LDL-cholesterol of 7.2 mmol l-1). Lovastatin was administered at a dosage of 40-80 mg for 20 weeks and was discontinued for 5 weeks thereafter. Parallel to a 47% fall in plasma LDL cholesterol, there was a significant reduction (P < 0.01) in erythrocyte membrane cholesterol:phospholipid molar ratio, while erythrocyte membrane fluidity assessed by diphenylhexatriene (DPH) fluorescence polarization increased significantly (P < 0.01). Discontinuation of lovastatin resulted in the reversal of erythrocyte membrane composition and fluidity to pre-treatment values.

MeSH terms

  • Adult
  • Aged
  • Cholesterol / blood*
  • Cholesterol, LDL / blood
  • Erythrocyte Deformability / drug effects*
  • Erythrocyte Membrane / drug effects
  • Erythrocyte Membrane / metabolism
  • Female
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Lipids / blood
  • Lovastatin / therapeutic use*
  • Male
  • Middle Aged

Substances

  • Cholesterol, LDL
  • Lipids
  • Cholesterol
  • Lovastatin